• In May 2026, Sarah Cannon Research Institute announced a collaboration with Pfizer to accelerate development of Pfizer’s oncology portfolio using SCRI’s Accelero clinical trial model, while Pfizer also reported strong Phase 2 data for its 25-valent pneumococcal vaccine candidate in infants compared with Prevnar 20 and moved it into pivotal Phase 3 trials.
• A particularly important insight is 25vPnC’s much stronger immune response against serotype 3, a persistent driver of serious pediatric pneumococcal disease, combined with a research alliance aimed at speeding oncology trials through more efficient, community-based study execution.
• We’ll now assess how this promising pediatric 25-valent vaccine data may influence Pfizer’s longer-term investment narrative built around pipeline-led growth.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Pfizer Investment Narrative Recap

To own Pfizer today, you have to believe that its large pipeline can offset looming patent cliffs and earnings pressure, while management protects the dividend and improves cash generation. The new 25-valent infant pneumococcal data and SCRI oncology alliance support that pipeline-led story but do not materially change the key near term catalyst, which remains late stage readouts across oncology and vaccines, or the biggest risk, which is revenue erosion from expiring exclusivities.

Among recent announcements, the May 2026 collaboration with Sarah Cannon Research Institute stands out as most relevant here, because it directly targets the same oncology pipeline that analysts see as central to Pfizer’s future. If Accelero meaningfully shortens study timelines for cancer assets, it could enhance the impact of positive vaccine news like 25vPnC by improving overall R&D productivity at a time when patent expirations and drug pricing pressure are front of mind.

Yet despite this promising news flow, investors should also understand the growing risk that aggressive drug pricing reform could...

Pfizer’s narrative projects $54.9 billion revenue and $9.2 billion earnings by 2029. This implies a 4.6% yearly revenue decline but an earnings increase of about $1.7 billion from $7.5 billion today.

Uncover how Pfizer's forecasts yield a $29.19 fair value, a 12% upside to its current price.

Exploring Other Perspectives

While recent vaccine data are encouraging, the most pessimistic analysts were still projecting revenues around US$49.0 billion by 2029 and earnings near US$6.7 billion, so this new information could meaningfully reshape how you weigh those downside scenarios against the potential of oncology and vaccines to surprise on the upside.

Explore 22 other fair value estimates on Pfizer - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Pfizer research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Pfizer research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pfizer's overall financial health at a glance.

Want Some Alternatives?

Our top stock finds are flying under the radar-for now. Get in early:

• Find 46 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.